NCT06547164View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 27, 2024

Primary Completion Date

August 20, 2025

Study Completion Date

August 20, 2025

Conditions
Healthy Participants
Interventions
DRUG

Midazolam

Midazolam will be administered orally.

DRUG

Camizestrant

Camizestrant will be administered orally.

DRUG

Carbamazepine

Carbamazepine will be administered orally.

Trial Locations (1)

HA1 3UJ

Research Site, Harrow

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY